

## Correction Notice – Appendix 3Y

Dublin, Ireland – December 6, 2024 – Oneview Healthcare PLC (ASX:ONE), refers to the Appendix 3Y released to the market on 3 December 2024 in relation to Mark Cullen’s interest.

It has come to Oneview's attention that there was a minor typographical error in the Appendix 3Y of Mark Cullen that Oneview wishes to correct. The correction relates to the number of CDIs held by Mr Cullen.

The correct Appendix 3Y is attached to this announcement.

### About Oneview Healthcare PLC

Serving hospitals and healthcare systems, academic medical centers, and pediatric hospitals worldwide, Oneview Healthcare’s Care Experience Platform (CXP) provides a unified set of digital tools in a single bedside solution. Oneview’s CXP connects patients, families, and care teams with services, education, and information during hospital stays. Fully automated, integrated, and personalized, hospitals using Oneview positively impact safe and timely discharges while streamlining nursing workflows

For more information, please visit [www.oneviewhealthcare.com](http://www.oneviewhealthcare.com)

**Directors** B Nelson (Chair) | N Asaria | M Cullen | J Fitter | D Lyons | J Rooney

Oneview Healthcare plc

2<sup>nd</sup> Floor, Avoca Court, Temple Road, Blackrock, Co. Dublin, A94 R7W3 Ireland

P +353 1 524 1677 E [info@oneviewhealthcare.com](mailto:info@oneviewhealthcare.com) [oneviewhealthcare.com](http://oneviewhealthcare.com)

Irish Company Reg: 513842

ARBN 610 611 768

VAT Number 9853271T

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	ONEVIEW HEALTHCARE PLC
<b>ABN</b>	610 611 768

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mark Cullen
<b>Date of last notice</b>	22 <sup>nd</sup> March 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	2 <sup>nd</sup> December 2024
<b>No. of securities held prior to change</b>	11,587,286 CDIs held in respect of ordinary shares 1,182,065 Restricted Share Units over CDIs held in respect of ordinary shares (unvested)
<b>Class</b>	Restricted Share Units over CDIs held in respect of ordinary shares
<b>Number acquired</b>	234,375 Restricted Share Units over CDIs held in respect of ordinary shares
<b>Number disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	11,587,286 CDIs held in respect of ordinary shares. 1,416,440 Restricted Share Units over CDIs held in respect of ordinary shares (unvested)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Restricted Share Units under the NED & Consultant RSU Plan as approved by shareholders at AGM on 30 October 2024

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

<sup>+</sup> See chapter 19 for defined terms.